Skip to content
OpenCapital
Get started

Allogene Therapeutics ALLO AFS and Trading Securities - Unrealized Loss Position Fair Value

Other financials

Income statement

See full
Revenue-—
Operating income-$46.1M+29.3%
Net income-$42.6M+28.7%
EPS (diluted)-$0.18+35.7%

Balance sheet

See full
Cash & equivalents$40.6M-23.0%
Total debt$81.1M-8.9%
Total equity$278.9M-27.6%
Total assets$396.0M-22.1%

Cash flow

See full
Operating cash flow-$12.9M+75.6%
CapEx$9.0K-90.9%
Free cash flow-$12.9M+75.6%

Valuation

See full
Market cap$711.02M+164%
Enterprise value$751.47M+146%

Profitability

See full
Operating margin-1,241,813.6%-2,018,140pp
Net margin-1,170,863.6%-2,007,890pp
FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full
Return on equity-52.3%-5.7pp
Debt / equity0.3×+0.1×
Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's afs and trading securities - unrealized loss position fair value.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Allogene Therapeutics's AFS and trading securities - unrealized loss position fair value?
Allogene Therapeutics (ALLO) reported AFS and trading securities - unrealized loss position fair value of $0 in Q1 2026.
What is the long-term trend for Allogene Therapeutics's AFS and trading securities - unrealized loss position fair value?
Over 5 years (2020 to 2025), Allogene Therapeutics's AFS and trading securities - unrealized loss position fair value has grown at a -100.0% compound annual growth rate (CAGR), from $5M to $0.